PDCD1 and head and neck squamous cell carcinoma: In HNSCC, the anti‐PD‐1 antibodies pembrolizumab and nivolumab have received approval from the USA Food and Drug Administration and European Medicine's Agency for platinum‐refractory/relapsed or metastatic patients.52, 53